Citations

Clear

815 citation(s) found for "Tang, Yu".

Book-Shaped Acellular Fibrocartilage Scaffold with Cell-loading Capability and Chondrogenic Inducibility for Tissue-Engineered Fibrocartilage and Bone–Tendon Healing
Chen, Can , Liu, Fei , Tang, Yifu , Zheng, Cheng , Chen, Yang , Li, Muzhi , Zhao, Chunfeng , Sun, Lun‐Quan , Lü, Hongbin , Zheng, Cheng , Chen, Yang , Li, Muzhi , Lu, Hongbin , Qu, Jin , Cao, Yong Bing , Hu, Jianzhong

Mayo Clinic

ACS Applied Materials & Interfaces | January 9, 2019 | Volume: 11 | Issue: 3 | Pages: 2891-2907

10.1021/acsami.8b20563 | PMID 30620556 Get It

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need
Quiroz, Yakeel T. , Albensi, Benedict C. , Astell, Arlene , Babiloni, Claudio , Bahar‐Fuchs, Alex , Bowman, Gene L. , Chételat, Gaël , Ciro, Carrie , Cohen, Ann D. , Dilworth‐Anderson, Peggye, Dreux, Simone, Edland, Steven D. , Esbensen, Anna J. , Ewers, Michael , Fargo, Keith N. , Fortea, Juan , González, Héctor M. , Gustafson, Deborah , Head, Elizabeth , Hendrix, James A. , Hofer, Scott M. , Johnson, Leigh , Jutten, Roos J. , Kilborn, Kerry, Martins, Ralph N. , Morris, Martha Clare , Murray, Melissa E. , Parra, Mario A. , Roe, Catherine M. , Santos, Octavio A. , Scarmeas, Nikolaos , Schneider, Lon S. , Schupf, Nicole , Sikkes, Sietske A.M. , Snyder, Heather M. , Sohrabi, Hamid R. , Strydom, André , Muñiz‐Terrera, Graciela , Teunissen, Charlotte E. , Lent, Debora Melo van , Weinborn, Michael , Wesselman, Linda M.P. , Arenaza-Urquijo, Eider, Teunissen, Charlotte E , Fortea, Juan , Murray, Melissa E , Babulal, Ganesh M. , Arenaza‐Urquijo, Eider M. , Bell, J. Simon , Brickman, Adam M. , Dodge, Hiroko Hayama , Evered, Lisbeth Anne , Gonzalez, Hector M , Lanctôt, Krista L. , Manly, Jennifer J. , Mielke, Michelle M. , Oh, Esther S , Rissman, Robert A. , Stern, Yaakov , Tang, Yi , Wilcock, Donna M. , Zetterberg, Henrik , O’Bryant, Sid E. , Head, Elizabeth , Cohen, Annie

Mayo Clinic

Alzheimer's & Dementia | December 13, 2018 | Volume: 15 | Issue: 2 | Pages: 292-312

10.1016/j.jalz.2018.09.009 | PMID 30555031 Get It

Abstract Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART ) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross‐PIA white paper that provides both a concise “state‐of‐the‐science” report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.
Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections
Charlton, Carmen , Babady, Esther , Ginocchio, Christine C. , Hatchette, Todd F. , Jerris, Robert C. , Loeffelholz, Mike J., McCarter, Yvette S., Novak-Weekley, Susan, Widen, R, Drews, Steven J. , Babady, N. Esther , Tang, Yi-Wei , Li, Yan , Miller, Melissa B. , Schuetz, Audrey N. , Tang, Yi‐Wei

Mayo Clinic

Clinical Microbiology Reviews | December 7, 2018 | Volume: 32 | Issue: 1 | Pages: No page available

10.1128/cmr.00042-18 | PMID 30541871 Get It

Respiratory viral infections are associated with a wide range of acute syndromes and infectious disease processes in children and adults worldwide. Many viruses are implicated in these infections, and these viruses are spread largely via respiratory means between humans but also occasionally from animals to humans.
Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features
Wu, Jiang , Cai, Muyan , Li, Shiyong , Bei, Jin‐Xin , Wang, Fang , Ling, Yihong , Rodrı́guez-Bigas, Miguel A. , Dignam, James J. , Mao, Mao , Li, Jibin , Guo, Yun‐Miao , Wu, Xiaoyan , Kong, Lingheng , Tang, Jing‐Hua, Li, Chao‐Feng, Chen, Jie‐Rong, Ye, Ming‐Zhi, Guo, Fengming, Han, Peng , Wan, Desen, Li, Li , Xu, Rui‐Hua , Ding, Pei-Rong , Group, Written on behalf of AME Colorectal Cancer Cooperative, Xu, Rui‐Hua , Jiang, Wu , Xu, Rui-Hua , Hampel, Heather , Frayling, Ian M. , Sinicrope, Frank A. , Kerr, David , Rosell, Rafael , Kong, Ling‐Heng, Tang, Jing-Hua , Wu, Xiaodan , Ou, Qingjian , Ye, Ming-Zhi, Wang, Qiwei , Pan, Zhizhong , Group, Written on behalf of AME Colorectal Cancer Cooperative

Mayo Clinic

International Journal of Cancer | December 6, 2018 | Volume: 144 | Issue: 9 | Pages: 2161-2168

10.1002/ijc.32044 | PMID 30521064 Get It

The prevalence of Lynch syndrome (LS) varies significantly in different populations, suggesting that ethnic features might play an important role. We enrolled 3330 consecutive Chinese patients who had surgical resection for newly diagnosed colorectal cancer. Universal screening for LS was implemented, including immunohistochemistry for mismatch repair (MMR) proteins, BRAFV600E mutation test and germline sequencing. Among the 3250 eligible patients, MMR protein deficiency (dMMR) was detected in 330 (10.2%) patients. Ninety‐three patients (2.9%) were diagnosed with LS. Nine (9.7%) patients with LS fulfilled Amsterdam criteria II and 76 (81.7%) met the revised Bethesda guidelines. Only 15 (9.7%) patients with absence of MLH1 on IHC had BRAFV600E mutation. One third (33/99) of the MMR gene mutations have not been reported previously. The age of onset indicates risk of LS in patients with dMMR tumors. For patients older than 65 years, only 2 patients (5.7%) fulfilling revised Bethesda guidelines were diagnosed with LS. Selective sequencing of all cases with dMMR diagnosed at or below age 65 years and only of those dMMR cases older than 65 years who fulfill revised Bethesda guidelines results in 8.2% fewer cases requiring germline testing without missing any LS diagnoses. While the prevalence of LS in Chinese patients is similar to that of Western populations, the spectrum of constitutional mutations and frequency of BRAFV600E mutation is different. Patients older than 65 years who do not meet the revised Bethesda guidelines have a low risk of LS, suggesting germline sequencing might not be necessary in this population.
Abstract 063: Urinary Mitochondrial DNA Copy Number Identifies Renal Mitochondrial Injury in Renovascular Hypertensive Patients Undergoing Renal Revascularization
Lerman, Lilach O. , Eirin, Alfonso , Herrmann, Sandra M. , Saad, Ahmed , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

Hypertension | December 6, 2018 | Volume: 72 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.72.suppl_1.063 Get It

Background: We have previously shown in patients with renovascular hypertension (RVH) that elevated urinary mtDNA copy numbers represent surrogate markers of renal mitochondrial injury. Revascularization with percutaneous transluminal renal angioplasty (PTRA) can lead to acute renal reperfusion injury. However, whether PTRA induces renal mitochondrial injury remains unknown. Methods: We prospectively measured urinary copy number of the mtDNA genes cytochrome-c oxidase-3 (COX3) and NADH dehydrogenase subunit-1 (ND1) by qPCR in 5 RVH patients before and 24hrs after PTRA. Five additional patients were treated before and during PTRA with the mitoprotective drug elamipretide (ELAM, 0.05 mg/kg/hr IV infusion). Healthy volunteers (HV) served as controls (n=5). Results: Baseline blood pressure was similarly elevated in both RVH groups, and eGFR lower than HV (Table). Baseline urinary COX3 and ND1 levels were similarly higher in both RVH groups compared with HV (Fig. A), and directly correlated with serum creatinine levels (R 2 =0.74, p=0.001 and R 2 =0.45, p=0.033, respectively). Over 3 months, eGFR increased only in ELAM-treated patients (Fig. B). Furthermore, the rise in urinary mtDNA 24hrs after PTRA was blunted in PTRA+ELAM versus PTRA+Placebo, and inversely correlated with the change in eGFR of 3 months after PTRA (Fig. C). Conclusion: PTRA induces an acute rise in urinary mtDNA levels, likely reflecting renal mitochondrial injury due to reperfusion injury that inhibits renal recovery. Mitoprotection in this cohort limited PTRA-associated mitochondrial injury and improved renal outcomes after revascularization.
Utilization of Anterolateral Thigh Flap and Transverse Cervical Recipient Vessels for Head and Neck Cancer Patients With Former Neck Dissection and Irradiation
Lin, Kuan-Wen , Huang, Tony Chieh‐Ting , Cheng, Hsu-Tang

Mayo Clinic

Annals of Plastic Surgery | December 5, 2018 | Volume: 82 | Issue: 4 | Pages: 415-419

10.1097/sap.0000000000001647 | PMID 30516556 Get It

PurposeFree flap reconstruction in head and neck cancer patients with prior tumor resection, neck dissection, and irradiation is clinically challenging. The purpose of this study was to investigate the reliability and outcome of using the anterolateral thigh (ALT) flap and transverse cervical recipient vessels for microvascular reconstruction in patients with depleted vessels in the head and neck region caused by previous surgery and irradiation.MethodsBetween January 2015 and December 2017, microsurgical head and neck reconstruction was performed using the ALT flap and transverse cervical artery (TCA) as the recipient vessel in 15 patients who had undergone previous neck dissections and irradiation for cancer treatment. All patients had a “vessel-depleted neck” resulting from severe scarring and radiation fibrosis. Clinical data of each patient were recorded.ResultsAll ipsilateral TCAs were found to be damage free. Subsequently, free ALT flaps were revascularized using the TCAs. One patient developed venous thrombosis, and another patient developed arterial thrombosis. They were both salvaged within 6 hours postoperatively. No flap failure or mortalities were reported within the 30-day postoperative period. Two patients developed orocutaneous fistula and were further managed with wound care. The mean follow-up time was 11.9 ± 6.0 months (range, 5–23 months). Five patients died during the follow-up period from cancer progression.ConclusionsThe use of the free ALT flap and TCA as the recipient vessel provides favorable microsurgical outcomes in patients with depleted recipient vessels in the head and neck region caused by previous neck dissections and radiation therapy.
Staged inset of free flaps for complex microsurgical head and neck reconstruction to ensure total flap survival
Huang, Tony Chieh‐Ting , Ciudad, Pedro , Manrique, Oscar J. , Agko, Mouchammed , Tang, Phoebe Yueh‐Bih, Sabbagh, M. Diya , Huang, Tony C T , Sabbagh, M Diya , Mouchammed, Agko , Chen, Shih‐Heng , Chen, Hung‐Chi

Mayo Clinic

Microsurgery | November 29, 2018 | Volume: 38 | Issue: 8 | Pages: 844-851

10.1002/micr.30370 | PMID 30488493 Get It

AbstractIntroductionMicrosurgical reconstruction of complex head and neck defects often requires reliable tissue in multiple spatial configurations to achieve good functional and aesthetic outcomes. In addition to robust perforators, flap inset and wound closure require great caution to minimize complications especially in the presence of trismus with limited space for inset. This report describes the technique and results of our staged approach to flap inset which increases the chance of total flap survival in complex head and neck reconstructions.MethodsFrom February 2010 to August 2016, a total of 53 patients were identified via a retrospective chart review. Patients who were suspected to have a high risk of vascular compromise and subsequently underwent complex head and neck reconstruction with staged inset of anterolateral thigh (ALT) flaps were included. The flap was inset only partially at the recipient site initially with fewer sutures. At a second stage, after neovascularization from surrounding tissue was established, the flap was partially elevated, divided and mobilized on its own pedicle for definitive inset.ResultsFifty‐one patients had complete survival of flaps and had uneventful postoperative course. Six cases required immediate re‐exploration to release wound tension or reposition the pedicle. Of these, 4 flaps were salvaged, 2 failed due to small perforators despite anastomosis revision. The flap survival rate was 96.2% and the average time between 2 stages was 24 days (range, 21–28).ConclusionStaged flap inset can improve free flap survival in complex head and neck reconstructions.
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Hong, David S. , LoRusso, Patricia , Hamid, Omid , Jankú, Filip , Kittaneh, Muaiad , Catenacci, Daniel V.T. , Chan, Emily , Bekaii‐Saab, Tanios , Loberg, Robert D., Amore, Benny , Hwang, Yuying C., Tang, Rui , Ngarmchamnanrith, Gataree, Kwak, Eunice L., Hong, David S , Bekaii-Saab, Tanios S , Gadgeel, Shirish M.

Mayo Clinic

Clinical Cancer Research | November 13, 2018 | Volume: 25 | Issue: 8 | Pages: 2403-2413

10.1158/1078-0432.ccr-18-1341 | PMID 30425090 Get It

Abstract Purpose: This first-in-human, open-label phase I study evaluated AMG 337, an oral, highly selective small-molecule inhibitor of MET in advanced solid tumors. Patients and Methods: Patients enrolled into dose-escalation cohorts received AMG 337 up to 400 mg once daily or up to 250 mg twice daily, following a modified 3+3+3 design. Dose expansion was conducted in MET-amplified patients at the maximum tolerated dose (MTD). Primary endpoints included assessment of adverse events (AEs), establishment of the MTD, and pharmacokinetics; clinical response was a secondary endpoint. Results: The safety analysis set included 111 patients who received ≥1 dose of AMG 337. Thirteen patients had ≥1 AE qualifying as dose-limiting toxicity. The MTD was determined to be 300 mg once daily; the MTD for twice-daily dosing was not reached. Most frequent treatment-related AEs were headache (63%) and nausea (31%). Grade ≥3 treatment-related AEs occurred in 23 patients (21%), most commonly headache (n = 6) and fatigue (n = 5). Maximum plasma concentration occurred at 3.0 hours following 300-mg once-daily dosing, indicating AMG 337 absorption soon after treatment. Objective response rate was 9.9% (11/111; 95% CI, 5.1%–17.0%) in all patients and 29.6% (8/27; 95% CI, 13.8%–50.2%) in MET-amplified patients; median (range) duration of response was 202 (51–1,430+) days in all patients and 197 (64–1,430+) days in MET-amplified patients. Conclusions: Oral AMG 337 was tolerated with manageable toxicities, with an MTD and recommended phase II dose of 300 mg once daily. The promising response rate observed in patients with heavily pretreated MET-amplified tumors warrants further investigation. See related commentary by Ma, p. 2375
The Reciprocity between Radiotherapy and Cancer Immunotherapy
Wang, Yifan , Liu, Zhi-Gang, Yuan, Hengfeng , Deng, Weiye , Li, Jing , Huang, Yu-Hui , Kim, Betty Y.S. , Story, Michael D. , Jiang, Wen , Huang, Yuhui , Huang, Yuhui , Jiang, Wen , Kim, Betty Y S

Mayo Clinic

Clinical Cancer Research | November 9, 2018 | Volume: 25 | Issue: 6 | Pages: 1709-1717

10.1158/1078-0432.ccr-18-2581 | PMID 30413527 Get It

Abstract The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.